ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded TEVA PHARMACEUTICALS USA, INC. a firm-fixed price delivery order under the base contract SPE2DP20D0002 for the supply of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, with a total contract value of $343,526.40. The award, issued on July 14, 2026, specifies the delivery of 18 packages of the vaccine, identified by NSN 6505016420106 and NDC 51285-0138-50, to be shipped to Naval Hospital Beaufort in Beaufort, SC, with the freight origin at Fort Detrick, MD. Delivery is due by July 21, 2026, with FOB destination terms placing responsibility for freight and delivery costs on the contractor. Each shipment must be properly marked with the Transportation Control Number W25MWY61940723 and the Required Delivery Date 203 (Julian date), and packaging must comply with DoD traceability standards, excluding parcel post. The vaccine, manufactured under CAGE 0AZ22, is subject to government inspection and acceptance at the destination. The contract includes no option quantities, modifications, or variance allowances, and the award was issued without a set-aside or socioeconomic designation. While the document references tracking systems and internal government codes such as PR 7017485350 and IPD 02, it does not specify payment office details, accounting appropriation data, invoicing protocols, or the identity of the contracting officer’s representative. Standard FAR clauses, Section K representations, Section H special requirements, and evaluation factors are not present in the available documentation. The order reflects a routine pharmaceutical procurement under a DoD logistics framework, leveraging standard supply chain controls and labeling practices for biological products.